AI ECG Predicts Atrial Fibrillation Risk. 12/07/25

Welcome to Cardiology Today – Recorded December 07, 2025. This episode summarizes 5 key cardiology studies on topics like Aficamten and left ventricular dysfunction. Key takeaway: AI ECG Predicts Atrial Fibrillation Risk.. Article Links: Article 1: Finerenone and Cardiovascular Outcomes According to Baseline Kidney Function in Patients With Heart Failure: The FINEARTS-HF Trial. (JACC. Heart failure) Article 2: Efficacy and Safety of Aficamten in Children and Adolescents With Obstructive Hypertrophic Cardiomyopathy: Study Design and Rationale of CEDAR-HCM. (Circulation. Heart failure) Article 3: Artificial intelligence-enabled electrocardiographic sex discordance and the risk of incident atrial fibrillation: a multi-national cohort study. (Heart rhythm) Article 4: High Subcutaneous Nerve Activity in Noise-Associated Ventricular Arrhythmias. (Heart rhythm) Article 5: Temporal Change in Right Ventricular Pacing Ratio and Its Association with Cardiac Function and Arrhythmia: A Linear Mixed-Effects Model Analysis. (Heart rhythm) Full episode page: https://podcast.explainheart.com/podcast/ai-ecg-predicts-atrial-fibrillation-risk-12-07-25/ Featured Articles Article 1: Finerenone and Cardiovascular Outcomes According to Baseline Kidney Function in Patients With Heart Failure: The FINEARTS-HF Trial. Journal: JACC. Heart failure PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41351608 Summary: Finerenone is established to reduce the risk of worsening heart failure events and cardiovascular death. This benefit applies to patients with heart failure with mildly reduced or preserved ejection fraction. The FINEARTS-HF trial investigated whether this known efficacy of finerenone varies according to a patient’s baseline kidney function. Article 2: Efficacy and Safety of Aficamten in Children and Adolescents With Obstructive Hypertrophic Cardiomyopathy: Study Design and Rationale of CEDAR-HCM. Journal: Circulation. Heart failure PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41347307 Summary: Aficamten, a cardiac myosin inhibitor, improved exercise capacity, health status, and symptoms in adults with obstructive hypertrophic cardiomyopathy, as demonstrated in the phase three SEQUOIA-HCM trial. This medication directly targets the underlying hypercontractility responsible for hypertrophic cardiomyopathy. The CEDAR-HCM trial is evaluating the efficacy and safety of aficamten in children and adolescents with obstructive hypertrophic cardiomyopathy, addressing a critical unmet need given the limited treatment options for pediatric hypertrophic cardiomyopathy. Article 3: Artificial intelligence-enabled electrocardiographic sex discordance and the risk of incident atrial fibrillation: a multi-national cohort study. Journal: Heart rhythm PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41352445 Summary: This study successfully developed and externally validated an artificial intelligence enabled electrocardiogram model for sex prediction. The model achieved an Area Under the Curve of 0.91 on the C. O. D. E. minus 15 percent dataset and 0.90 on the M. I. M. I. C. minus I. V. dataset. This tool generates a sex discordance score, which provides a quantifiable measure related to incident atrial fibrillation risk beyond binary sex classification. Article 4: High Subcutaneous Nerve Activity in Noise-Associated Ventricular Arrhythmias. Journal: Heart rhythm PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41352444 Summary: Environmental noise acts as a contributing factor to cardiovascular disease and arrhythmias, a process linked to autonomic nervous system dysregulation. The mechanisms driving noise-induced arrhythmogenesis remain unclear. Understanding subcutaneous nerve activity and heart rate variability is crucial for elucidating the role of autonomic nervous system modulation in these ventricular arrhythmias. Article 5: Temporal Change in Right Ventricular Pacing Ratio and Its Association with Cardiac Function and Arrhythmia: A Linear Mixed-Effects Model Analysis. Journal: Heart rhythm PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41352443 Summary: Right ventricular pacing induces electrical and mechanical dyssynchrony, which can influence left ventricular dysfunction and contribute to heart failure. The long-term impact of temporal increases in the right ventricular pacing ratio on left ventricular remodeling and arrhythmia occurrence has been unclear. This retrospective longitudinal cohort study investigates these associations to provide crucial insights into patient management following right ventricular pacing implantation. Transcript Today’s date is December 07, 2025. Welcome to Cardiology Today. Here are the latest research findings. Article number one. Finerenone and Cardiovascular Outcomes According to Baseline Kidney Function in Patients With Heart Failure: The FINEARTS-HF Trial. Finerenone is established to reduce the risk of worsening heart failure events and cardiovascular death. This benefit applies to patients with ...